Torrent Pharma has recently announced the Q3 FY22 results. The company has registered revenue at Rs 2,108 crores up by 6 per cent. The gross margins are at 70 per cent, EBITDA margins at 28 per cent. The EBITDA is at Rs 585 crores was down by five per cent. The profit before tax is at Rs 357 crores and net profit after tax is at Rs 249 crores, down by 16 per cent.

Samir Mehta, Chairman, Torrent Pharma said, "Due to the prolonged delays in reinspection of our US facilities on account of the pandemic, coupled with higher than anticipated pricing pressure, our US business has been adversely affected during this quarter. We remain hopeful of our prospects in the US market as soon as the facilities are reinspected. We have initiated cost optimisation measures which should help us get back on track with respect to margins in the upcoming quarters. Our India business continues to be on a strong footing delivering significantly higher than market growth during the quarter.”